
Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into real-world impact.
Senior vice president of medicine and regulatory, U.S., at Boehringer Ingelheim. In her role, Clerisme-Beaty oversees medical strategy for an organization of more than 1,000 employees
Prior to joining Boehringer, Clerisme-Beaty was an assistant professor at Johns Hopkins University, where she completed advanced training in pulmonary critical care medicine. Her academic and clinical background informs a holistic approach to chronic disease management, emphasizing multidisciplinary, integrated solutions for complex conditions such as obesity and diabetes.

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into real-world impact.